The biochemistry of ketogenesis and its role in weight management, neurological disease and oxidative stress
Keywords:
ketogenesis, metabolism, weight management, neurological disease, oxidative stressAbstract
The section of mammalian metabolism known as ketogenesis is responsible for creating ketone bodies. In this mechanism, the liver responds to decreased glucose availability by producing the tiny, water-soluble molecules acetoacetate, D-3-hydroxybutyrate, and propanone. While ketone bodies are always present in small amounts in healthy people, dietary changes and some pathological circumstances can raise the concentrations of these substances in living organisms. The systemic effects of ketogenic diet (KD), despite its recent widespread usage, are poorly known and can range from potentially dangerous results to medically advantageous outcomes depending on the situation. Here, we discuss the metabolism and molecular signaling of ketone bodies before relating the biology of ketone bodies to debates about their potential or actual health benefits. According to the findings of this research, a KD can be used as a natural treatment for weight loss in fat individuals. This is a one-of-a-kind research that will follow the effects of a KD for 24 weeks. The patients' lipid, total cholesterol, LDL cholesterol, and glucose levels all decreased significantly, while their HDL cholesterol levels increased significantly. The adverse effects of medications widely used for weight loss in such individuals were not noted in patients on the KD.
Downloads
References
Alter A, Engelstad K, Hinton V, et al., Long-term clinical course of Glut1 deficiency syndrome. J Child Neurol. 2015;30:160–169.
Cornejo E, Cabello A, Colombo C, et al., Sındrome de deficiencia del transportador de glucosa tipo 1 (SDGLUT-1) tratado con dieta cetogenica. Caso clınico. RevMedChile. 2007;135:631–635.
Deng-Bryant Y, Prins ML, Hovda DA, et al., KD prevents alterations in brain metabolism in young but not adult rats after traumatic brain injury. J Neurotrauma 2011; 28: 1813–1825.
Foster, D.W. Malonyl-coa: The regulator of fatty acid synthesis and oxidation. J. Clin. Investig. 2012, 122, 1958–1959.
Gordon J. Effect of glucose load on attention and seizures in glucose transporter type 1 deficiency syndrome. Pediatr Neurol Briefs. 2010;24:25–26.
Grabacka M, Pierzchalska M, Dean M, Reiss K. Regulation of ketone body metabolism and the role of PPARα. International journal of molecular sciences. 2016 Dec 13;17(12):2093.
Haces ML, Hernandez-Fonseca K, Medina-Campos ON, et al., Antioxidant capacity contributes to protection of ketone bodies against oxidative damage induced during hypoglycemic conditions. Exp Neurol 2008; 211: 85–96.
Ito Y, Oguni H, Ito S, et al., A modified Atkins diet is promising as a treatment for glucose transporter type 1 deficiency syndrome. Dev Med Child Neurol. 2011;53:658–663.
Jiang Y, Lu Y, Jia M, et al., KD attenuates spatial and item memory impairment in pentylenetetrazol-kindled rats. Brain Res.2016;1646:451–458.
Kashiwaya Y, Bergman C, Lee JH, et al., A ketone ester diet exhibits anxiolytic and cognition-sparing properties and lessens amyloid and tau pathologies in a mouse model of AD. Neurobiol Aging. 2013;34:1530–1539.
Khurana DS, Valencia I, Goldenthal MJ, et al., Mitochondrial dysfunction in epilepsy. Semin Pediatr Neurol. 2013;20:176–187.
Klein P, Janousek J, Barber A, et al., KD treatment in adults with refractory epilepsy. Epilepsy Behav. 2010;19:575–579.
Klein P, Tyrlikova I, Mathews GC. Dietary treatments in adults with refractory epilepsy: a review. Neurology. 2014;83:1978–1985.
Lambrechts D, Wielders L, Aldenkamp A, et al., The KD as a treatment option in adults with chronic refractory epilepsy: efficacy and tolerability in clinical practice. Epilepsy Behav.2012;23:310–314.
Leen WG, Taher M, Verbeek MM, et al., GLUT 1 deficiency syndrome into adulthood: a follow-up study. J Neurol. 2014;261:589–599.
Maalouf M, Rho JM and Mattson MP. The neuroprotective properties of calorie restriction, the KD, and ketone bodies. Brain Res Rev 2009; 59: 293–315.
Mochel F, Hainque E, Gras D, et al., Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency. J Neurol Neurosurg Psychiatry. 2016;87:550–553.
Nakamura S, Osaka H, Muramatsu S, et al., Gene therapy for a mouse model of glucose transporter-1 deficiency syndrome. Mol Genet Metab Rep.2017;10:67–74.
Newport M, Vanitallie T, Kashiwaya Y, et al., A new way to produce hyperketonemia: use of ketone ester in a case of Alzheimer’s. Alzheimers Dement. 2015;11:99–103.
Noh HS, Hah YS, Nilufar R, et al., Acetoacetate protects neuronal cells from oxidative glutamate toxicity. J Neurosci Res 2006; 83: 702–709.
Phillips M, Murtagh D, Gilbertson L, et al., Low-fat versus KD in Parkinson’s disease: a pilot randomized controlled trial. Mov Disord. 2018;33:1306–1314.
Prins M. Diet, ketones, and neurotrauma. Epilepsia 2008; 49: 111–113.
Prins ML, Fujima LS and Hovda DA. Age-dependent reduction of cortical contusion volume by ketones after traumatic brain injury. J Neurosci Res 2005; 82: 413–420.
Raimann X, Marın V, Buron V, et al., Dieta cetogenica en epilepsia refractaria: eficacia, evolucion y complicaciones a largo plazo. Rev Chil Pediatr. 2007;78:477–481.
Ramm-Pettersen A, Stabell KE, Nakken KO, et al., Does KD improve cognitive function in patients with GLUT1-DS? A 6- to17-month follow up study. Epilepsy Behav. 2014;39:111–115.
Reger MA, Henderson ST, Hale C, et al., Effects of b-hydroxybutyrate on cognitionin memory-impaired adults. Neurobiol Aging. 2004;25:311–314.
Schoeler NE, Wood S, Aldridge V, et al., KDary therapies for adults with epilepsy: feasibility and classification of response. Epilepsy Behav. 2014;37:77–81.
Shaafi S, Mahmoudi J, Najmi S, et al., Modulatory role of KD in neuroinflammation: a possible drug n€aive strategy to treatment of Parkinson’s disease. Adv Biosci Clin Med. 2015;3:43–47
Sullivan PG, Rippy NA, Dorenbos K, et al., The KD increases mitochondrial uncoupling protein levels and activity. Ann Neurol 2004; 55: 576–580.
Taylor M, Sullivan D, Mahnken J, et al., Feasibility and efficacy data from a KD intervention in AD. Alzheimers Dement (N Y). 2018;4:28–36.
Veech RL, Chance B, Kashiwaya Y, et al., Ketone bodies, potential therapeutic uses. IUBMB Life 2001; 51: 241–247.
Ziegler DR, Ribeiro LC, Hagenn M, et al., KD increases glutathione peroxidase activity in rat hippocampus. Neurochem Res 2003; 28: 1793–1797.
Published
How to Cite
Issue
Section
Copyright (c) 2023 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
